Highly efficient labeling of antibodies with oligonucleotide labels

By removing glycans and utilizing non-covalent binding with the C'E loop or Cγ2-Cγ3 domain, the method achieves nearly 100% efficient antibody labeling with oligonucleotides, addressing the inefficiencies of current conjugation techniques.

JP2024543504AInactive Publication Date: 2024-11-21アクトム ジーエムビーエイチ
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024529124
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-15
Filing Date
2022-11-14
Publication Date
2024-11-21
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods for antibody-DNA conjugation suffer from statistical behavior, label dissociation, and low efficiency, particularly with non-covalent and covalent conjugation techniques, leading to inconsistent labeling and reduced shelf life.

Method used

A method involving the selective removal of glycans from antibodies, specifically the N-glycosides, and using a fast non-covalent binding step with the C'E loop or Cγ2-Cγ3 domain to facilitate high-potency labeling with oligonucleotides, achieving nearly 100% conjugation efficiency by maintaining oligonucleotides in place through affinity binding.

Benefits of technology

This approach ensures nearly 100% labeling of antibodies with oligonucleotides, overcoming low bimolecular rate constants and diffusion limitations, enabling consistent and efficient conjugation for applications requiring defined label valency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543504000001_ABST
    Figure 2024543504000001_ABST
Patent Text Reader

Abstract

The present invention includes a method for highly efficient selective labeling of antibodies with oligonucleotides. The method may involve selective removal of glycans from antibodies and replacing them with artificial glycosides, particularly N-glycosides containing oligonucleotides. The process is believed to be facilitated by oligonucleotide-induced orientation of the antibody C'E loop, and to a lesser extent, the Cγ2-Cγ3 domain. The method results in highly efficient labeling of antibodies.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention includes a method for highly efficient selective labeling of antibodies with oligonucleotides. The method may involve selective removal of glycans from antibodies and their replacement with artificial glycosides, particularly N-glycosides containing oligonucleotides. The process is believed to be facilitated by oligonucleotide-induced orientation of the antibody C'E loop, and to a lesser extent, the Cγ2-Cγ3 domain. The method results in highly efficient labeling of antibodies. [Background technology]

[0002] The two main approaches of antibody-DNA conjugation are non-covalent (e.g. biotin-streptavidin) or covalent conjugation methods. Non-covalent methods are prone to label dissociation during application, resulting in label hopping and short shelf life. Covalent conjugation methods are differentiated according to site-specific and non-selective conjugation. A further objective is the modification of antibodies to obtain labeled antibodies or antibodies with a precisely defined number of DNA labels. The degree of labeling affects many applications of antibody-DNA conjugates, especially labeling strategies involving unique molecular identifiers. Random labeling strategies are hindered by the statistical behavior of the conjugation reaction, and a degree of one label per antibody leads to conjugates containing a mixture of single-labeled, double-labeled and unlabeled antibodies. This behavior is common to both non-covalent (biotin-streptavidin) or covalent conjugation methods, since both approaches have a statistical reaction step. Strategies using site-specific conjugation are capable of generating antibody-DNA conjugates with a defined number of DNA labels, but this also introduces undesirable statistical behavior when the conjugation reaction is not exhaustive (100% efficient).

[0003] Short oligonucleotide sequences (less than 30 bp) do not show enhanced conjugation reactions but still exert statistical conjugation (McMahon NP, Jones JA, Kwon S, et al. Oligonucleotide conjugated antibodies permit highly multiplexed immunofluorescence for future use in clinical histopathology. J Biomed Opt. 2020;25(05):1. doi:10.1117 / 1.jbo.25.5.056004).

[0004] Consequently, methods to achieve global DNA conjugation of antibodies are highly desirable.

[0005] Chemoselective ligation reactions used in the selective targeting of small molecules have significant limitations - the inherent kinetic properties of bimolecular covalent reactions. Current chemoselective ligation reactions have been developed in the 10 4 ~10 5 M -1 min -1(Jencks, WP (1959) J. Am. Chem. Soc. 81, 475-481; Sayer, JM, Peskin, M. and Jencks, WP (1973) J. Am. Chem. Soc. 95, 4277-4287). Because covalent reactions have relatively low rate constants, high concentrations of reagents are required to make the reaction proceed at a useful rate. Chemoselective conjugation of biomolecules becomes increasingly less effective as the molecular weight of the reactants increases due to the low achievable concentrations of reactants, diffusion limitations, steric issues and unfavorable interactions between the reaction partners. Maerle et al. have demonstrated that antibody conjugation reactions with 60 bp oligonucleotides have unacceptably low yields (Maerle A V., Simonova MA, Pivovarov VD, et al. Development of the covalent antibody-DNA conjugates technology for detection of IgE and IgM antibodies by immuno-PCR. PLoS One. 2019; 14(1): 1-19. doi: 10.1371 / journal.pone.0209860). The efficacy of high-yield conjugation reactions, including simple click chemistry reactions used to conjugate oligonucleotides to antibodies using non-site-specific approaches, varies and is generally less than 30% and as low as only 5% for oligonucleotides larger than 50 bp. (Wiener J, Kokotek D, Rosowski S, Likert H, Meier M. Preparation of single- and double-oligonucleotide antibody conjugates and their application for protein analytics.Sci Rep.2020;10(1):1-12.doi:10.1038 / s41598-020-58238-6).

[0006] Approaches for selective carbohydrate modification are diverse, ranging from chemical and enzymatic oxidation of sugars (Wilchek and Bayer 1987; Bayer et al. 1988) and enzymatic transfer of fluorescently labeled sugars by glycosyltransferases (Gross and Brossmer 1988; Gross and Brossmer 1991). Strategies for the metabolic incorporation of sialic acid derivatives into cell surface glycoconjugates have also been developed (Kayser et al. 1992; Keppler et al. 1995; Lee et al. 1999; Lemieux and Bertozzi 1998; Schmidt et al. 1998). The chemical synthesis of various activated sugars and their enzymatic transfer starting from L-galactose was described by Hallgren and Hindsgaul (1995). A method was developed in which biotinylated sugars were transferred to N-acetyllactosamine derivatives by fucosyltransferase, and further that transfer using UDP-GalNAc and azide as bi-orthogonal label (Hang et al. 2003).Finally, a strategy was created to transfer nucleotide sugars of UDP-Gal with keto modifications using a mutant of recombinant bovine β4Gal-T1 (Khi dekel et al. 2003).

[0007] The low bimolecular rate constants of chemoselective ligation reactions can be overcome if they are preceded by fast non-covalent binding of the reaction partners. An example of this principle is when an aptamer is functionalized with a reactive electrophilic group and binds to a target protein (elastase) on the neutrophil cell surface through non-covalent association, as described by Charlton, J., Sennello, J. and Smith, D. (1997) Chem. Biol. 4, 809-816). Upon binding, the reactive phosphonate forms an irreversible covalent adduct with a serine residue in the active site of the enzyme. However, this requires a complex and unique design of a label for each target, and no such strategy has been devised for labels with structural elements other than the reactive chemoselective chemical groups of antibodies and small molecules.

[0008] Simulations show high amplitude motions of Fc N-glycans of IgG antibodies, where glycan residues dynamically bind and detach from the Fc surface, exposing the glycan termini to bulk solvent for enzymatic modification in an open conformation. This is consistent with NMR studies of Fc glycan accessibility, which has two distinct states: one in which the glycans interact with the polypeptide surface and are buried, and the other in which the glycans are freely exposed to the solvent and do not undergo glycan-polypeptide interactions (Lee HS, Im W. Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering. Sci Rep. 2017;7(1):1-10. doi:10.1038 / s41598-017-12830-5). This behavior has been detected in different glycan forms and may be extended to other sugar-containing compounds with similar molecular weights, such as natural glycans containing N-glycosides. Summary of the Invention

[0009] The present invention provides the first method for the selective global labeling of antibodies with oligonucleotides. This is advantageous in applications where comprehensive labeling of oligonucleotide-conjugated antibodies is necessary, e.g. methods used to translate detection signals from proteins to the DNA level, highly multiplexed strategies for protein analysis assays (Ali, MM et al. Rolling circle amplification: a versatile tool for chemical biology, materials science and medicine. Chem. Soc. Rev. 43, 3324-3341 (2014); Karakus U, Thamamongood T, Ciminski K, et al. MHC class II proteins mediate cross-species entry of bat influenza viruses. Nature. 2019. doi:10.1038 / s41586-019-0955-3; Lundberg, M., Eriksson, A., Tran, B., Assarsson, E. & Fredriksson, S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res.39, e102-e102(2011)). These are useful when combined with next generation sequencing (NGS) techniques or sequential fluorescence hybridization methods, allowing proteins to be quantified in parallel, for example with CITEseq or SABER.(Stoeckius, M. et al. Simultaneous epitope and transcriptome measurement in single cells. Nat. Methods 14, 865-868(2017); Saka, S. K. et al. Immuno-SABER enables highly multiplexed and amplified protein imaging in tissues. Nat. Biotechnol. 37, 1080-1090(2019)). All of these applications require chemically defined antibody conjugates with known label valency and potency to produce consistent numerical results.

[0010] The present invention is also advantageous in any method that uses a coupling scheme to facilitate efficient conjugation by applying a rapid non-covalent coupling step between the antibody C'E loop or / and Cγ2-Cγ3 domain and a payload such as an oligonucleotide.

[0011] The object of the present invention is to provide a method for selective and highly efficient labeling of antibodies with oligonucleotides. This can be achieved by using a concentration of at least 1 μM of oligonucleotide in the reaction mixture that allows affinity binding between the antibody and the oligonucleotide to occur. This can also be achieved by introducing a conjugable (handle) sugar moiety into asparagine-297 of IgG or a conformationally related amino acid of IgG, including, for example, endoglycosidase-based removal of the natural conserved asparagine N-glycan after the innermost GlcNAc moiety, if present, to ensure enhanced attachment of the functionalized N-glycoside and reacting the functionalized N-glycoside payload with the conjugation handle to overcome statistical conjugation reaction constraints.

[0012] Payloads are high molecular weight moieties for which efficient conjugation reactions are limited by physical, chemical or conformational effects.

[0013] The payload is advantageously an oligonucleotide or a modified oligonucleotide, which may be linked to a further labeling moiety, such as a fluorophore.

[0014] In a first aspect, the present invention provides a process for labelling an antibody with an oligonucleotide, comprising the steps of: (a) reacting an antibody with an oligonucleotide conjugated to a reactive group to form a covalent bond between the oligonucleotide and the antibody; Including, The process provides a method for preparing a method for the preparation of a medicament for use in a pharmaceutical composition comprising the steps of:

[0015] At physiological pH, antibodies have an affinity for oligonucleotides that is sufficient to hold the oligonucleotide in place, thereby increasing the efficiency of subsequent conjugation reactions between reactive groups attached to the oligonucleotide and groups on the antibody, thereby covalently linking the oligonucleotide to the antibody.

[0016] As used herein, the term "antibody" is used interchangeably with "immunoglobulin" and includes polyclonal antibodies, monoclonal antibodies, multispecific antibodies, e.g., bispecific antibodies, chimeric antibodies, humanized antibodies, human antibodies, and any other modified immunoglobulin molecules that contain an antigen recognition site, so long as the antibody exhibits the desired biological activity and contains at least the CH2 portion of at least one heavy chain. Preferably, the antibody is a monoclonal antibody. The antibody may be a member of any of the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses, (isotypes) thereof (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), based on the identity of the constant domains of their heavy chains, called alpha, delta, epsilon, gamma, and mu, respectively. The different classes of immunoglobulins have different and well-known subunit structures and three-dimensional conformations. Preferably, the antibody is an IgG antibody, more preferably IgG1 or IgG4. The term "antibody" is also intended to include conjugates of antibodies, such as conjugates with polyethylene glycol, PEG.

[0017] Furthermore, unless the context requires otherwise, the term "antibody" should be understood to encompass complete antibodies, as well as antibody fragments comprising the antigen-binding region and CH2 domain of the complete antibody, including scFv-CH2-CH3 fusion proteins. Antibodies can be produced by hybridomas, or by synthetic means, such as recombinant DNA techniques, phage display or yeast display techniques, or using transgenic mice, or by solution or solid phase peptide synthesis.

[0018] The antibody is preferably an IgG antibody. Preferably, the antibody is commercially available. Preferably, the antibody is known to be used in diagnostic methods. Preferably, the antibody is known to be used in therapy. Suitable antibodies for use in the present invention include trastuzumab, pertuzumab and combinations thereof.

[0019] The concentration of oligonucleotide in the reaction mixture is at least 1 μM. Preferably, the concentration of oligonucleotide is at least 10 μM or at least 50 μM or at least 70 μM or at least 100 μM or at least 500 μM, more preferably, the concentration of oligonucleotide is at least 1 mM. This concentration of oligonucleotide increases the rate of covalent binding, resulting in nearly 100% of the antibody being labeled. "Nearly 100%" or "close to 100%" of the antibody being labeled, as used herein, means that more than 90%, preferably more than 95%, more preferably more than 98%, and most preferably more than 99% of the antibody is labeled. The oligonucleotide is believed to diffuse into the pocket between the heavy chains and form a non-covalent bond. This increases the concentration of oligonucleotide present in the pocket, thereby improving the kinetics of the covalent binding reaction. The low bimolecular rate constant of the chemoselective ligation reaction is overcome, as it is preceded by rapid non-covalent association of oligonucleotides.

[0020] Preferably, each heavy chain in the antibody is labeled with an oligonucleotide. Thus, if an antibody molecule has two heavy chains, it is labeled with two oligonucleotides. It is desirable to label as close to 100% of the antibody as possible. It can be difficult to separate unlabeled antibody from labeled antibody. The presence of unlabeled antibody reduces the signal generated and increases background noise.

[0021] Oligonucleotides used to label antibodies are generally at least 30 bases in length, e.g., at least 40 bases, at least 50 bases, at least 60 bases, at least 70 bases, at least 80 bases, at least 90 bases, or at least 100 bases in length. Preferably, the oligonucleotide contains 40 to 150 nucleotides, e.g., 50 to 120 or 60 to 100 nucleotides.

[0022] Oligonucleotides may include RNA or DNA and may be single-stranded or double-stranded. Nucleotides forming nucleic acids may be chemically modified, for example, to improve the stability of the molecule, improve its bioavailability, confer additional activity to it, and / or provide additional negative charges. For example, pyrimidine bases may be modified at the 6- or 8-position, and purine bases at the 5-position with halogens such as CH3 or I, Br or Cl. Modification of pyrimidine bases may also include N-alkylation, ... 2 H3, 0 6 -CH3,N 6 -CH3 and N 2 Also includes -CH3. Modifications at the 2' position of the sugar moiety, "sugar modifications," generally add an NH2, F or OCH3 group. Modifications can also include 3' and 5' modifications, such as capping.

[0023] Alternatively, modified nucleotides such as morpholino nucleotides, locked nucleic acids (LNA) and peptide nucleic acids (PNAs) can be used. Morpholino oligonucleotides are constructed from different morpholino subunits, each of which contains one of the four genetic bases (adenine, cytosine, guanine and thymine) linked to a six-membered morpholine ring. The subunits are linked by non-ionic phosphorodiamidate intersubunit linkages to obtain morpholino oligonucleotides. LNA monomers are characterized in that the furanose ring conformation is restricted by a methylene linker connecting the 2'-O position to the 4'-C position. PNA is an analog of DNA in which the backbone is a pseudopeptide rather than a sugar.

[0024] The reactive group may be linked directly to the oligonucleotide. Alternatively, the reactive group may be linked to the oligonucleotide via a spacer. The spacer may be a linear or branched C1-C 200 Alkylene group, C2-C 200 Alkenylene group, C2-C 200 Alkynylene group, C3-C 200 Cycloalkylene group, C5-C 200 Cycloalkenylene group, C8-C 200 Cycloalkynylene group, C7-C200 Alkyl arylene group, C7-C 200 Aryl alkylene group, C8-C 200 Arylalkenylene group, C9-C 200 Optionally, the alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, cycloalkynylene, alkylarylene, arylalkylene, arylalkenylene and arylalkynylene groups may be substituted, and optionally, the groups may be interrupted by one or more heteroatoms, preferably 1 to 100 heteroatoms, preferably O, S and NR 11 where R 11 is hydrogen, halogen, hydroxy, C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl groups. Most preferably, the heteroatom is O.

[0025] Suitable spacers include (poly)ethylene glycol diamines (e.g., 1,8-diamino-3,6-dioxaoctane or equivalents containing longer ethylene glycol chains), polyethylene glycol or polyethylene oxide chains, polypropylene glycol or polypropylene oxide chains, and 1,x-diaminoalkanes, where x is the number of carbon atoms in the alkane. Preferably, the spacer is polyethylene glycol, more preferably 2,2'-[oxybis(2,1-ethanediyloxy)]diethanol (PEG4).

[0026] Preferably, the present invention relates to a process for labeling an antibody with an oligonucleotide. (a) deglycosylating conserved N-glycosylated amino acids in the CH2 domain of the antibody heavy chain; (b) reacting the deglycosylated antibody with an oligonucleotide conjugated to a reactive group to form a covalent bond between the oligonucleotide and the deglycosylated antibody. Including, The concentration of the oligonucleotide conjugate is at least 1 μM; Provide a process.

[0027] The term "glycan" as used herein refers to a monosaccharide or oligosaccharide chain linked to a protein. A glycan is attached to a protein via the C-1 carbon of one sugar, which may be unsubstituted (monosaccharide) or may be substituted at one or more of its hydroxyl groups (oligosaccharide). Generally, naturally occurring glycans contain from one to about ten sugar moieties.

[0028] The glycans of a glycoprotein can be monosaccharides. Generally, the monosaccharide glycans of a glycoprotein consist of a single N-acetylglucosamine, glucose, mannose or fucose covalently attached to the protein.

[0029] Glycans can also be linear or branched oligosaccharides. The sugar attached directly to the protein is called the core sugar. A sugar that is not attached directly to the protein but is attached to at least two other sugars is called an internal sugar. A terminal sugar is a sugar that is not attached directly to the protein but is attached to a single other sugar, i.e., does not bear a further sugar substituent on one or more of its other hydroxyl groups. For the avoidance of doubt, there may be multiple terminal sugars on the oligosaccharide of a glycoprotein, but only one core sugar. The end of the oligosaccharide attached directly to the protein is called the reducing end. The other end of the oligosaccharide is called the non-reducing end of the glycan.

[0030] A glycan can be an O-linked glycan, an N-linked glycan, or a C-linked glycan. In an N-linked glycan, a monosaccharide or oligosaccharide glycan is attached to a protein through an N-atom in an amino acid of the protein, typically through the amide nitrogen in the side chain of an asparagine (Asn) or arginine (Arg). For example, a glycan is attached to a protein through an N-glycosidic bond. The asparagine substituted by the glycan on its side chain is typically part of the sequence Asn-X-Ser / Thr, where X is any amino acid except proline, and Ser / Thr is either serine or threonine. A variety of chains exist for N-linked glycans.

[0031] N-glycosylation of immunoglobulins is well known. Immunoglobulins are generally composed of two heavy chains and two light chains linked by disulfide bonds. The chains are further classified into constant and variable domains. Within the constant regions, particularly the heavy chain constant regions, there are many known conserved N-glycosylation sites on asparagine. When an antibody or immunoglobulin comprises two heavy chains, preferably both heavy chains are glycosylated, i.e. at least one glycan is present on each heavy chain. The location of the glycosylation site within the CH2 region varies depending on the isotype. For example, in IgG immunoglobulins the conserved N-glycosylation site is asparagine 297 (conventional literature amino acid numbering), for IgA1 it is asparagine 144, for IgA2 it is asparagine 133 and / or asparagine 205; for IgM it is asparagine 207; for IgE asparagine 146 and asparagine 252 may be glycosylated; for IgD the glycosylation site is asparagine 225. Preferably, when an immunoglobulin comprises two heavy chains, both heavy chains are glycosylated at one or more of the conserved N-glycosylation sites.

[0032] The N-glycosylated amino acid is preferably asparagine 297.

[0033] As shown in Figure 1, an N-glycosylated amino acid is attached to a glycan with an innermost core N-acetylglucosamine (GlcNAc) moiety attached directly to the amino acid. This GlcNAc moiety is attached to multiple galactose, mannose, fructose and / or additional N-acetylglucosamine moieties to form the glycan. As a first step, the antibody can be deglycosylated to remove one or more of the sugar units from the glycan, preferably leaving the innermost or core N-acetylglucosamine. Preferably, only the innermost core N-acetylglucosamine is left.

[0034] Deglycosylation can be performed using enzymes such as sialidases and / or galactosidases and / or endoglycosidases. Endoglycosidases can be used to remove the native conserved asparagine N-glycan after the innermost GlcNAc moiety. Suitable endoglycosidases include peptide-N-glycosidae F (PNGase F), endoglycosidase F (Endo F), including Endo F1, Endo F2 and Endo F3, endoglycosidase H (Endo H), endoglycosidase S (Endo S) and endoglycosidase S2 (Endo S2). Particularly preferred are the Fc-specific endoglycosidases EndoS2 (Genovis) or EndoS (New England Biolabs), which hydrolyze Fc glycans to the innermost N-acetylglucosamine (GlcNAc) moiety in some subclasses and species of IgG.

[0035] Alternatively, antibodies having only a single N-acetylglucosamine moiety attached to the N-glycosylated amino acid can be generated by expression of monoclonal antibodies in the presence of swainsonine or in modified host organisms.

[0036] It is believed that the removal of glycans results in an improved binding surface within the antibody for nucleic acids. The absence of glycans allows for increased affinity binding between the antibody and the oligonucleotide. This affinity binding effectively holds the oligonucleotide in place, enhancing the efficiency of the subsequent reaction to covalently attach the oligonucleotide to the modified deglycosylated antibody.

[0037] In one option, reactive groups on the oligonucleotides are crosslinked to the antibody. Methods for performing suitable crosslinking reactions and suitable reactive groups are known in the art and are as described in ThermoScientific Crosslinking technical handbook (2012) "Easy molecular bonding crosslinking technology Reactivity chemistries, applications and structure references". Oligonucleotides may be conjugated to reactive groups or sulfhydryl groups that can react with primary amines in the antibody to form covalent bonds linking the oligonucleotide to the antibody. Antibodies (especially IgG antibodies) generally have 10-15 readily available lysine amines that can react with reactive groups to bind to oligonucleotides. Alternatively, photochemical reactions can be performed to link oligonucleotides to antibodies through nucleophilic or active hydrogen groups.

[0038] Suitable reactive groups capable of reacting with primary amines include isothiocyanates, isocyanates, acyl azides, NHS esters, sulfonyl chlorides, aldehydes, glyoxals, epoxides, oxiranes, carbonates, aryl halides, imidoesters, carbodiimides, anhydrides, and fluorophenyl esters. Preferably, the reactive group is an NHS ester or an imidoester.

[0039] Suitable reactive groups capable of reacting with sulfhydryl groups include haloacetyls, maleimides, aziridines, acrylic alloys, arylating agents, vinyl sulfones, pyridyl disulfides, TNB thiols, and disulfide reducing agents.

[0040] Suitable photoreactive groups include aryl azides, azidomethylcoumarins, benzophenones, anthraquinones, certain diazo compounds, diazirines, and psoralen derivatives.

[0041] Amine-Reactive Groups Primary amines are present at the N-terminus of each polypeptide chain and in the side chains of lysine (Lys, K) amino acid residues. Because these primary amines are positively charged at physiological pH, they occur primarily on the exterior of native protein tertiary structures, and they are readily accessible to conjugation reagents introduced into aqueous media. Primary amines are particularly nucleophilic, which facilitates conjugation with several reactive groups, including isothiocyanates, isocyanates, acyl azides, NHS esters, sulfonyl chlorides, aldehydes, glyoxals, epoxides, oxiranes, carbonates, aryl halides, imidoesters, carbodiimides, anhydrides, and fluorophenyl esters. Most of these conjugate to amines by either acylation or alkylation. NHS esters and imidoesters are the most common amine-specific functional groups incorporated into protein crosslinking and labeling reagents.

[0042] NHS Ester NHS esters are reactive groups formed by carbodiimide activation of carboxylate molecules. NHS ester-activated crosslinkers react with primary amines to form stable amide bonds at physiological to slightly alkaline conditions (pH 7.2-9). The reaction releases N-hydroxysuccinimide (NHS). NHS ester crosslinking reactions are most commonly performed at pH 7.2-8.5 for 0.5-4 hours at room temperature (20°C) or 4°C in phosphate, carbonate-bicarbonate, HEPES, or borate buffers.

[0043] Sulfo-NHS esters are identical to NHS esters except that they contain a sulfonate group (-SO3) on the N-hydroxysuccinimide ring. This charged group does not affect the reaction chemistry, but does tend to increase the water solubility of crosslinkers that contain it. In addition, the charged group can be used in cell surface crosslinking procedures because it prevents the sulfo-NHS crosslinker from penetrating cell membranes. Examples of NHS and sulfo-NHS are disuccinimidyl suberate (DSS) and bis(succinimidyl) suberate (BS3 or sulfo-DSS) amine-to-amine crosslinkers. DSS is not directly soluble in water, but once dissolved, it can penetrate through cell membranes and act inside cells. BS3 is water soluble, but when charged, it cannot penetrate cell membranes, limiting BS3 crosslinking to the surface of intact cells.

[0044] Imidoester Imidoester crosslinkers react with primary amines to form amidine bonds. Imidoester crosslinkers react rapidly with amines at alkaline pH, but have a short half-life. As the pH becomes more alkaline, the half-life increases and reactivity with amines increases; therefore crosslinking is more efficient when performed at pH 10 than at pH 8. Amidine formation is favored between pH 8-10, although reaction conditions below pH 10 may result in side reactions. Studies with monofunctional alkyl imidates indicate that conjugations with only one functional imidoester group can be formed at pH < 10. Intermediate N-alkyl imidates form in the lower pH range and are either crosslinked with another amine in the immediate vicinity to give an N,N'-amidine derivative or converted to an amidine bond.

[0045] Sulfhydryl-reactive crosslinks Sulfhydryls, also called thiols, are found in proteins in the side chains of cysteine ​​(Cys, C) amino acids. Pairs of cysteine ​​sulfhydryl groups are frequently linked by disulfide bridges (-SS-) within or between polypeptide chains as the basis of natural tertiary or quaternary protein structures. Generally, only free or reduced sulfhydryl groups (-SH) are available for reaction with thiol-reactive compounds.

[0046] Sulfhydryls are present in most proteins, but are less abundant than primary amines, so cross-linking through sulfhydryl groups is more selective and precise. Because sulfhydryl groups in proteins are often involved in disulfide bonds, cross-linking at these sites generally does not significantly modify the underlying protein structure or block binding sites. The number of available (i.e., free) sulfhydryl groups can be easily controlled or modified; they can be generated by reducing native disulfide bridges, or introduced into molecules by reacting with primary amines using sulfhydryl-adding reagents such as 2-iminothiolane (Traut's Reagent), N-succinimidyl S-acetylthioacetate (SATA), N-succinimidyl S-acetylthiopropionate (SATP), or N-succinimidyl S-acetyl(thiotetraethylene glycol) (SAT(PEG)4).

[0047] Sulfhydryl-reactive chemical groups are well known in the art and include haloacetyls, maleimides, aziridines, acrylic alloys, arylating agents, vinyl sulfones, pyridyl disulfides, TNB thiols, and disulfide reducing agents. Most of these groups conjugate to sulfhydryls either by alkylation (usually forming a thioether bond) or by disulfide exchange (forming a disulfide bond).

[0048] Haloacetyls have the formula R-NH(C=O)CH2Halo, where R is an oligonucleotide and an optional linker. Preferred haloacetyls include iodoacetyl or bromoacetyl groups.

[0049] Maleimide groups have the structure H2C2(CO)2NR, where R is an oligonucleotide and an optional linker. Maleimide groups react specifically with sulfhydryl groups when the pH of the reaction mixture is between 6.5 and 7.5, resulting in the formation of a stable thioether bond.

[0050] Pyridyl disulfides have the structure RSS-(C5H5N), where R is an oligonucleotide and an optional linker. Pyridyl disulfides react with sulfhydryl groups over a wide pH range (optimum pH 4-5) to form disulfide bonds. During the reaction, disulfide exchange occurs between the -SH group of the molecule and the 2-pyridyldithiol group of the reagent. As a result, pyridine-2-thione is released, which can be measured spectrophotometrically to monitor the progress of the reaction (A max =343 nm).

[0051] Photoreactive crosslinking Photoactivatable (or photochemical) crosslinking reactions require energy from light to initiate the reaction. Photoreactive groups are chemically inert compounds that become reactive when exposed to ultraviolet or visible light. Virtually all types of photoreactive groups used in reagents for crosslinking applications must be exposed to ultraviolet light (UV light) to activate the molecule. The use of photoreactive groups can be advantageous because they allow the oligonucleotide to be attached to the antibody and affinity binding with the antibody to occur. The mixture can then be exposed to UV light to cause the formation of a covalent bond between the antibody and the oligonucleotide.

[0052] Photoreactive groups that can be used as reactive groups conjugated to oligonucleotides to form covalent bonds to antibodies include aryl azides, azidomethylcoumarins, benzophenones, anthraquinones, certain diazo compounds, diazirines, and psoralen derivatives. Preferred groups are aryl azides and diazirines.

[0053] Aryl azides contain an aryl group substituted with an azide group (N=N=N). Aryl azides are conjugated to oligonucleotides. Upon exposure to UV light, a nitrene group is formed, which can initiate addition reactions involving insertion into double bonds or CH and NH sites.

[0054] Diazirine groups have the formula R-CHN2, where R is an oligonucleotide and an optional linker. When exposed to UV light, a carbene intermediate is formed that can form a covalent bond with an amino acid side chain that contains a nucleophilic or active hydrogen group.

[0055] Alternatively, if the antibody has been deglycosylated by the process of the invention, some or all of the glycans can be replaced with oligonucleotides. Methods for carrying out this process are known in the art, including those described in U.S. Pat. No. 99,873,736. This method has previously been used to attach small molecules to glycans. It has not previously been used to attach larger molecules such as oligonucleotides.

[0056] In another aspect, the invention relates to a method comprising: (a) introduction of a conjugable sugar, including endoglycosidase-based removal of the native conserved asparagine N-glycan after the innermost GlcNAc moiety, if present; (b) attachment of a functional N-glycoside; and (c) reacting the functional N-glycoside payload with a conjugation handle.

[0057] Thus, the method comprises: (a) deglycosylating conserved N-glycosylated amino acids in the CH2 domain of the antibody heavy chain; (b) conjugating a functional group to the modified antibody deglycosylated antibody to form a modified antibody; (c) reacting the modified antibody with an oligonucleotide conjugated to a reactive group to form a covalent bond between the oligonucleotide and the modified antibody; It may include, wherein the reactive group reacts with the functional group to form a covalent bond; and The concentration of the oligonucleotide conjugate is at least 1 μM.

[0058] The antibody is modified by linking a functional group. Preferably, the modified GlcNAc moiety is formed by attaching a sugar moiety that includes a functional group. This can be accomplished by contacting the antibody with a sugar moiety having one or more functional groups in the presence of an enzyme that links the sugar moiety, preferably to an N-acetylglucosamine moiety on the antibody. Suitable enzymes include galactosyltransferases, such as p(1,4)-galactosyltransferase, p(1,3)-N-galactosyltransferase, β(1,4)-galactosyltransferase. β(1,4)-galactosyltransferases can contain mutant catalytic domains such as those described in U.S. Pat. No. 7,482,133, including GalT(Y289L), GalT(Y289I) and GalT(Y289N).

[0059] As used herein, the term "sugar" is used to refer to a monosaccharide and the term "sugar moiety" refers to a monosaccharide derivative, which contains one or more functional groups. The sugar moiety is preferably derived from a sugar or amino sugar, such as galactose, mannose, glucose, glucosamine, galactosamine, N-acetylglucosamine, N-acetylgalactosamine, fucose or sialic acid. More preferably, the sugar moiety is preferably derived from galactose, galactosamine, mannose, glucose, N-acetylgalactosamine or N-acetylglucosamine.

[0060] The sugar moiety may further comprise a nucleotide, such as a nucleoside monophosphate or a nucleoside diphosphate. Examples of such nucleotides include uridine diphosphate (UDP), guanosine diphosphate (GDP), thymidine diphosphate (TDP), cytidine diphosphate (CDP) and cytidine monophosphate (CMP). Preferably, the nucleotide is UDP. Suitable nucleoside monophosphates and nucleoside diphosphates are described in WO 2009 / 102820.

[0061] Examples of sugar moieties that contain nucleotides include uridine 5'-diphospho-N-acetylazidogalactosamine (GalNAz-UDP), UDP-N-acetyl-alpha-D-galactosamine (6-AzGal-UDP), 6-AzGalNAc-UDP, uridine 5'-diphospho-N-acetylazidogalactosamine (4-AzGalNAz-UDP), UDP-6-azido-6-deoxy-D-glucose (6-AzGalNAz-UDP), UDP-6-azido-6-deoxy-D-glucose (6-AzGlc-UDP), 6-AzGlcNAz-UDP, 2-ketoGal-UDP, 2-N-propionylGalNAc-UDP, 2-(butyric acid)-3-yl ionoic acid (3-methyl-2-propanoic acid)-3-methyl-2-propano ... acid)amide)-2-deoxy-galactose-UDP, 6-chloro-6-deoxygalactose-UDP (6-ClGal-UDP), 6-thio-6-deoxygalactose-UDP (6-HSGal-UDP), 2-chloro-2-deoxygalactose-UDP (2-ClGal-UDP), 2-thio-2-deoxygalactose-UDP (2-HSGal-UDP), 6-chloroacetamide-6-deoxygalactose-UDP (6-GalNAcCl-UDP), 6-thioacetamide -6-deoxygalactose-UDP (6-GalNAcSH-UDP), 2-chloroacetamido-2-deoxygalactose-UDP (2-GalNAcCl-UDP), 2-thioacetamido-2-deoxygalactose-UDP (2-GalNAcSH-UDP), 3-thiopropanoylamido-2-deoxygalactose-UDP (2-GalNProSH-UDP) and 4-thiobutanoylamido-2-deoxygalactose-UDP (2-GalNBuSH-UDP). Preferably, the sugar moiety is uridine 5'-diphospho-N-acetylazidogalactosamine (GalNAz-UDP) or 6-AzGalNAc-UDP.

[0062] Preferably, the sugar moiety is a galactosamine-derived moiety that is enzymatically attached using β-1,4-galactosyltransferase.

[0063] The enzymatic coupling of functional groups is generally carried out at 4 to 50°C, preferably 10 to 45°C, and most preferably 30 to 37°C.

[0064] The enzymatic attachment of functional groups is generally carried out at about pH 4 to about pH 9, preferably at pH 5.5 to pH 8.0, and most preferably at pH 6 to pH 7.5.

[0065] As used herein, a "functional group" may be selected from an azide group, a keto group, an alkynyl group, a thiol group or a precursor thereof, a halogen, a sulfonyloxy group, a halogenated acetamide group, a mercaptoacetamide group, and a sulfonylated hydroxyacetamide group.

[0066] As used herein, an "azido group" is defined as -N3R n where each R is independently selected from the group consisting of hydrogen, halogen, and an (optionally substituted) C1-C6 alkyl group, and n is 0, 1, or 2. Preferably, R is H and n is 1 or 2. More preferably, n is 0.

[0067] Suitable azide-containing sugar moieties include uridine 5'-diphospho-N-acetylazidogalactosamine (UPD-GalNAz).

[0068] As used herein, a "keto group" is defined as a -R1(O)R2 group, where R1 is an optionally substituted C1-C6 alkyl group and R2 is independently selected from the group consisting of hydrogen, halogen, and an optionally substituted C1-C6 alkyl group. Preferably, R2 is hydrogen.

[0069] As used herein, a "thiol group" is defined as a -R2SH group, where R2 is an optionally substituted C1-C6 alkyl group. Preferably, R3 is a C1, C2, C3, or C4 alkyl group.

[0070] As used herein, a "thiol group precursor" is defined herein as a -RSC(O)CH group, where R, and preferred embodiments thereof, are as defined above for a thiol group. Most preferably, said thiol-precursor is -CHCHCHSC(O)CH, -CHCHSC(O)CH, -CHSC(O)CH or -SC(O)CH, preferably -SC(O)CH. During the process for the preparation of a modified glycoprotein, the thiol precursor is converted to a thiol group.

[0071] As used herein, a "sulfonyloxy group" is defined as a -R4OS(O)2R5 group, where R4 is an optionally substituted C1-C6 alkyl group, R5 is a C1-C6 alkyl group, 24 Aryl groups, C7-C 24 Alkylaryl groups and C7-C 24 R4 is preferably a C1, C2, C3 or C4 alkyl group. R5 is preferably a C1 to C4 alkyl group, a C6 to C7 alkyl group, a C8 to C9 alkyl group, a C10 to C11 alkyl group, a C11 to C12 alkyl group, a C12 to C13 alkyl group, a C13 to C14 alkyl group, a C14 to C15 alkyl group, a C15 to C16 alkyl group, a C16 to C17 alkyl group, a C17 to C18 alkyl group, a C18 to C19 alkyl group, a C20 to C21 alkyl group, a C21 to C22 alkyl group, a C22 to C23 alkyl group, a C23 to C24 alkyl group, a C24 to C25 alkyl group, a C25 to C31 alkyl group, a C26 to C27 alkyl group, a C27 ​​to C31 alkyl group, a C28 to C31 alkyl group, a C29 to C3 12 Aryl groups, C7-C 12 Alkylaryl group or C7-C 12 R5 is an arylalkyl group. More preferably, R5 is a C1, C2, C3 or C4 alkyl group, a phenyl group or a p-tolyl group. Most preferably, the sulfonyloxy group is a mesylate group, -OS(O)2CH3, a benzenesulfonate group (-OS(O)2(C6H5) or a tosylate group (-OS(O)2(C6H4CH3).

[0072] As used herein, a "halogenated acetamide group" is defined as a -NHC(O)R6X group, where R6 is an optionally substituted C1-C6 alkyl group and X is F, Cl, Br or I. Preferably, R6 is hydrogen or a C1, C2, C3 or C4 alkyl group. Preferably, X is Cl or Br, more preferably, X is Cl.

[0073] As used herein, "mercaptoacetamido" is defined as the group -NHC(O)R7SH, where R7 is an optionally substituted C1-C6 alkyl group. Preferably, R7 is a C1, C2, C3 or C4 alkyl group. Preferred examples include mercaptoethanoylamido, mercaptopropanoylamido, mercaptobutanoylamido and mercapto-pentanoylamido groups, preferably mercaptopropanoylamido.

[0074] As used herein, a "sulfonylated hydroxyacetamide" is -NHC(O)R9OS(O)2R 10 group, where R is an optionally substituted C1-C6 alkyl group, and R 10 is a C1-C6 alkyl group, C6-C 24 Aryl groups, C7-C 24 Alkylaryl groups and C7-C 24 R is independently selected from the group consisting of arylalkyl groups. Preferably, R is a C1, C2, C3 or C4 alkyl group. R 10 is preferably a C1 to C4 alkyl group, 12 Aryl groups, C7-C 12 Alkylaryl group or C7-C 12 More preferably, R 10 is a C1, C2, C3 or C4 alkyl group, a phenyl group or a p-tolyl group. Most preferably, the sulfonyloxy group is a mesylate group -OS(O)2CH3, a benzenesulfonate group -OS(O)2(C6H5) or a tosylate group -OS(O)2(C6H4CH3).

[0075] As used herein, "halogen" is defined as fluorine, chlorine, bromine or iodine. Preferably, the halogen is chlorine or bromine.

[0076] As used herein, an "aryl" group is a C-C 12It refers to a monocyclic or bicyclic structure. Optionally, the aryl group can be substituted with one or more substituents. Examples of aryl groups are phenyl and naphthyl.

[0077] As used herein, "arylalkyl" and "alkylaryl" refer to groups containing at least 7 carbon atoms and may include monocyclic and bicyclic structures. Optionally, the arylalkyl and alkylaryl groups may be substituted with one or more substituents. An example of an arylalkyl group is benzyl. An example of an alkylaryl group is 4-t-butylphenyl.

[0078] As used herein, an "alkyl" group can contain 1 to 8 carbon atoms. It can be linear or branched or cyclic. An unsubstituted alkyl group can also contain a cyclic moiety. Optionally, an alkyl group is substituted with one or more substituents. Preferably, the alkyl is a C1, C2, C3 or C4 alkyl group. Examples of alkyl groups include methyl, ethyl, propyl, 2-propyl, t-butyl, pentyl, cyclopentyl, 1-hexyl, cyclohexyl, and the like.

[0079] As used herein, an "alkynyl" group includes a carbon-carbon triple bond and can contain 2 to 10 carbon atoms. A terminal alkynyl is an alkynyl group in which the triple bond is located at the terminal position of the carbon chain. Optionally, the alkynyl group is substituted with one or more substituents and / or interrupted by a heteroatom selected from the group of oxygen, nitrogen, and sulfur. Examples of alkynyl groups include ethynyl, propynyl, butynyl, octynyl, and the like.

[0080] As used herein, a "cycloalkynyl" group is a cyclic alkynyl group and may contain 3 to 10 carbon atoms. Optionally, the cycloalkynyl group is substituted with one or more substituents. An example of a cycloalkynyl group is cyclooctynyl. A preferred cycloalkynyl group is dibenzocyclooctyne.

[0081] As used herein, a "heterocycloalkynyl" group is a cycloalkynyl group interrupted by a heteroatom selected from the group of oxygen, nitrogen, and sulfur. Optionally, the heterocycloalkynyl group is substituted with one or more substituents. An example of a heterocycloalkynyl group is azacyclooctynyl.

[0082] As used herein, "optionally substituted" means that a group is selected from the group consisting of hydroxy, C1-C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C5-C 12 Cycloalkenyl groups, C8-C 12 Cycloalkynyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 It means that the silyl group may be substituted with one or more substituents selected from the group consisting of cycloalkyloxy groups, halogens, amino groups, oxo, and silyl groups. As used herein, a silyl group is a group represented by the formula (R 12 )Si-, where R 12 is C1~C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups and C3-C 12and cycloalkyloxy groups, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted, and the alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N and S.

[0083] The modified antibody, defined herein as comprising a functional group, reacts with an oligonucleotide conjugated to a reactive group to form a covalent bond between the oligonucleotide and the modified antibody. The oligonucleotide becomes conjugated to the modified antibody via a linker that comprises a covalent bond formed by reaction of the functional group and the reactive group.

[0084] The reaction of binding the oligonucleotide and the modified antibody is generally carried out at 4 to 50° C., preferably 10 to 45° C., and most preferably 30 to 37° C. The reaction is generally carried out at 4° C. overnight.

[0085] The reaction of binding the oligonucleotide and the modified antibody is generally carried out at about pH 4 to about pH 9, preferably pH 5.5 to pH 8.0, and most preferably pH 6 to pH 7.5.

[0086] The reactive group reacts with a functional group to form a covalent bond. Suitable reactive groups for forming a covalent bond with a functional group on a modified antibody are known in the art and are described, for example, in U.S. Patent No. 9,987,373.

[0087] When the functional group is an azide group, the linking of the modified antibody with the oligonucleotide conjugate preferably occurs via a cycloaddition reaction.In this case, the reactive group is preferably selected from the group consisting of an alkynyl group, preferably a terminal alkynyl group, and a cycloalkynyl group.A similar reaction can occur when the reactive group and the functional group are reversed, such that the reactive group is an azide group and the functional group is selected from the group consisting of an alkynyl group, preferably a terminal alkynyl group, and a cycloalkynyl group.Preferred cycloalkynyl groups include dibenzocyclooctyne.

[0088] When the functional group is a keto group, the linkage between the modified antibody and the oligonucleotide conjugate preferably occurs via selective conjugation with a hydroxylamine derivative or hydrazine, resulting in an oxime or hydrazone, respectively. In this case, the reactive group is preferably a primary amino group, such as a -NH2 group, an aminooxy group, such as -O-NH2, or a hydrazinyl group, such as -N(H)NH2. A similar reaction can occur when the reactive group and the functional group are reversed, such that the reactive group is a keto group and the functional group is a primary amino group.

[0089] When the functional group is an alkynyl group, the linkage between the modified antibody and the oligonucleotide conjugate preferably occurs via a cycloaddition reaction, preferably a 1,3-dipolar cycloaddition. In this case, the reactive group is preferably a 1,3-dipole, such as an azide, a nitrone, or a nitrile oxide. A similar reaction can occur when the reactive group and the functional group are reversed, such that the reactive group is an alkynyl group and the functional group is a 1,3-dipole.

[0090] When the functional group is a thiol group, the linkage between the modified antibody and the oligonucleotide conjugate preferably occurs via a Michael-type addition reaction. In this case, the reactive group is preferably an N-maleimidyl group in the case of a Michael-type addition, a halogenated acetamide group in the case of a nucleophilic substitution reaction, or a terminal alkene in the case of a thiol-ene reaction. A similar reaction can occur when the reactive group and the functional group are reversed, such that the reactive group is a thiol group and the functional group is an N-maleimidyl group, a halogenated acetamide group, or a terminal alkene.

[0091] When the functional group is a halogen, a halogenated acetamido group, a sulfonyloxy group, or a sulfonylated hydroxyacetamido group, the linkage between the modified antibody and the oligonucleotide conjugate preferably occurs via reaction with a thiol to form a thioether. In this case, the reactive group preferably comprises a thiol group. A similar reaction can occur when the reactive group and the functional group are reversed, such that the reactive group is a halogen, a halogenated acetamido group, a sulfonyloxy group, or a sulfonylated hydroxyacetamido group, and the functional group is a thiol.

[0092] However, the reactive groups can also include alcohol or amine groups.

[0093] In one preferred option, the functional and reactive groups are selected from: an azide group and a cycloalkynyl or alkynyl group; a thiol group and an N-maleimide, iodoacetamide, chloroacteamide or disulfide group; a ketone or aldehyde group and a hydrazine, acylhydrazine, aniline or alkoxyamine.

[0094] Preferably, the functional and reactive groups are selected from an azide group and a cycloalkynyl group, preferably the cycloalkynyl group is a cyclooctyne group, more preferably a dibenzocyclooctyne.

[0095] In another aspect, the present invention provides an antibody labelled with an oligonucleotide obtainable by the process according to the invention.

[0096] In another aspect, the invention relates to a kit for use in the process of the invention for labelling an antibody with an oligonucleotide, comprising: (i) an oligonucleotide conjugated to a reactive group; and optionally (ii) a compound comprising a functional group capable of forming a modified GlcNAc moiety, wherein the functional group and the reactive group are capable of reacting to form a covalent bond; and / or (iii) an Fc-specific endoglycosidase; and / or (iv) β-1,4-galactosyltransferase A kit comprising:

[0097] Preferred embodiments of the kit are as described for the process of the invention. The kit may further comprise instructions for carrying out the methods of the invention described herein.

[0098] The method according to the present invention is capable of achieving 90% or more efficiency of antibody conjugation for oligonucleotides larger than 50bp.Preferably, the method achieves 95% or more, 97.5% or more, 99% or more, and most preferably 100% efficiency.100% efficiency means that each antibody present is labeled with at least one oligonucleotide.Preferably, each heavy chain in an antibody molecule is labeled with at least one oligonucleotide. The invention will now be illustrated with reference to the following drawings: [Brief description of the drawings]

[0099] [Figure 1] Figure 1 shows the N-glycosylation of the antibody on residue asparagine 297. The Cγ2-Cγ3 domains are in contact with the glycoside. [Diagram 2] FIG. 2 shows the covalent non-selective conjugation of Trastuzumab and Pertuzumab. [Diagram 3]FIG. 3 shows highly efficient DNA conjugation of trastuzumab antibody. [Figure 4] FIG. 4 shows the MST measurement under the conditions in Table 1. [Diagram 5] FIG. 5 shows the MST measurement under the conditions in Table 2. [Figure 6] FIG. 6 shows the MST measurement under the conditions in Table 3. [Figure 7] FIG. 7 shows the MST measurement under the conditions in Table 4. [Figure 8] Figure 8 shows that oligonucleotide-labeled trastuzumab according to the example protocol results in a labeling efficiency of 99.2%. The 26 kD peak represents the light chain, the 52.1 kD peak represents the unlabeled heavy chain of the antibody, and the labeled heavy chain of the antibody is 74 kD. [Figure 9] FIG. 9 shows the labeling efficiency as a function of different concentrations of oligonucleotide label. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0100] Working Example Example 1 DNA labeling of trastuzumab antibody Rebuffering of the antibody is usually required before carbohydrate processing. 150 μg of trastuzumab antibody in solution is added to a 100 kDa centrifugal ultrafiltration unit (Amicon) attached to a collection tube. After adding the antibody, the filter unit was filled to 500 μl with TBS buffer (200 mM Tris; 1500 mM NaCl; pH 7.6) and centrifuged at 14,000 g for 3 min at 4° C. The flow-through was discarded. 500 μl of TBS was added and the filter was centrifuged again at 14,000 g for 10 min at 4° C. and the flow-through was discarded. The filter was turned upside down and placed in a new collection tube, which was briefly centrifuged (1000 g, 20 s) to collect the rebuffered antibody sample. The sample should have a minimum volume of approximately 30 μl. If not, add enough TBS to obtain a minimum volume of 30 μl.

[0101] Carbohydrate modification on the antibody hinge region begins with deglycosylation of asparagine-297 by the Fc-specific endoglycosidase EndoS2 (Genovis) or EndoS (New England Biolabs), which hydrolyzes Fc glycans up to the innermost N-acetylglucosamine (GlcNAc) moiety in some subclasses and species of IgG. The enzyme removes all glycoforms, including high-mannose, hybrid, complex, and bisected glycans. 26 μl of GlyclNATOR resin (Genovis) was transferred to a Mobicol "F" spin column (MoBiTec) mounted in a 1.5 ml Eppendorf. Washing of the resin was performed by connecting a syringe containing 2 ml of TBS. The resin was drained by a brief centrifugation (1000 g, 20 s). Antibody binding was performed by adding 30 μl of antibody solution to the resin and incubating at room temperature for 3 h. The digested antibody was collected by brief centrifugation (1000g, 20 sec) using a Mobicol column attached to a new clean 1.5 ml Eppendorf tube. To collect all the antibody, 10 μl of TBS was added to the resin and briefly centrifuged (1000g, 20 sec). The pooled antibody solution should have a volume of approximately 40 μl.

[0102] β-1,4-galactosyltransferase Y289L * (GalT) was used to enzymatically couple the azide-containing uridine 5'-diphospho-N-acetylazidogalactosamine disodium salt (UPD-GalNAz) to the exposed GlcNAc moiety to generate an azide-activated antibody reactive with the alkyne-bearing label. 0.5 μl of buffer additive (Genovis) was added to the antibody solution. GalT(Y2898L) enzyme was dissolved in 20 μl TBS and 1.3 μl of dissolved GalT was added to the antibody solution. 3 μl of reconstituted UDP-GalNAz (in 40 μl TBS) was added to the antibody solution. The solution was mixed by pipetting up and down and incubated overnight at 30°C protected from light.

[0103] To remove free UPD-GalNAz, 450 μl TBS was added to the antibody-GalT reaction and transferred to a 10 kDa centrifugal ultrafiltration unit (Amicon) attached to a collection tube. The unit was centrifuged at 14,000 g for 5 min at 4° C. and the flow-through was discarded. The azide-modified antibody sample was washed by adding 500 μl TBS and centrifuged at 14,000 g for 20 min at 4° C. and the flow-through was discarded. The sample was collected by inverting the unit in a new collection tube and centrifuged briefly (1000 g, 20 s).

[0104] To conjugate the oligonucleotides, 3 μl of 1 mM dibenzocyclooctyne-conjugated oligonucleotide (5'-DBCO-PEG4 oligonucleotide) was added to the antibody solution (20-30 μl) to promote replacement of the cleaved asn-297 glycan moiety with DNA. Since the Kd of DNA binding to the C'E loop or / and Cγ2-Cγ3 domain is in the micromolar range, effective concentrations in the submillimolar to millimolar range are required for complete replacement. The mixture was incubated overnight at 4 °C protected from light. The low bimolecular rate constant of the chemoselective ligation reaction is likely overcome as it is preceded by fast non-covalent binding of the oligonucleotides.

[0105] To detect the efficiency of antibody labeling, free oligonucleotides were removed and the efficiency of conjugated antibodies was determined by SDS-PAGE based electropherogram analysis. 100 μl of Pierce™ Protein A / G Agarose Resin (ThermoFisher Scientific) was packed into a Mobicol Spin column. The resin was washed with 2 ml of TBS and briefly centrifuged (1000 g, 20 s) to drain the resin. The entire antibody-oligonucleotide mixture was loaded onto the resin and incubated for 30 min at room temperature. After incubation, the resin was washed with 20 ml of PBS and briefly centrifuged. The antibody was eluted by adding 50 μl of elution buffer (pH 3) to the resin according to the manufacturer and incubated for 10 min at room temperature. The tube was briefly centrifuged (1000 g, 20 s) and the flow-through was collected in pH neutralizing buffer. The efficiency of labeling of the antibodies with oligonucleotides is determined using an Agilent Protein 230 chip on a Bioanalyzer (Agilent) (according to the manufacturer's instructions).

[0106] For comparison, covalent non-selective conjugation of antibodies was performed using the Thunder-Link® PLUS Oligo Conjugation System (Expedeon-antibody conjugation service provided by the manufacturer). As shown in Figure 2, this results in a labeling efficiency of approximately 10% under production conditions. Oligonucleotide conjugation of MW markers - lane 1, Pertuzumab unconjugated antibody - lane 2, Pertuzumab oligonucleotide conjugate - lane 3, Trastuzumab unconjugated antibody - lane 4, Trastuzumab oligonucleotide conjugate - lane 5. 4-12% Bis-Tris SDS-PAGE gel, performed in reduced samples and MOPS buffer. Left - SYBR Gold stain to detect oligonucleotide DNA, right - Instant Blue stain to detect protein. The estimated labeling efficiency is approximately 10% (based on SDS-PAGE Agilent Protein 230 chip performed on a Bioanalyzer 2100).

[0107] DNA-conjugated trastuzumab antibody was analyzed using SDS-PAGE Agilent Protein 230 chip on Bioanalyzer as shown in Figure 3. The horizontal scale is in kD (kilodaltons). The peak at 26.5 is the antibody light chain, while the peak at 53.7 is the antibody heavy chain. The molecular weight of the labeled heavy chain is 69.6 kD, which is consistent with the calculated molecular weight. SDS-PAGE Agilent Protein 230 Chip run on Bioanalyzer according to Table 1 (from Figure 3). The calculated labeling efficiency was 99.3% for one heavy chain (1-[peak 53.7 / [peak 53.7 -peak 69.6 ]]=0.993), the overall antibody labeling efficiency was 99.995%, which is considered to be 100% in practice. [Table 1]

[0108] Example 2 Antibody preparation 100-150 μg of Trastuzumab IgG antibody was used for this process. The antibody was rebuffered into RNAse-free ultrapure water (UPW) (Fisher Scientific, 2436574) using a 100 kD ultrafiltration column (Sigma, UFC510096), a volume of 450 μl of UPW was added, centrifugation was performed at 14,000 g for 10 min at 4°C, and the flow-through was discarded. This process was repeated once more. The column was inverted into a new collection tube and the antibody was collected by a brief spin (1,000 g, 20 s). The volume of the flow-through is approximately 20-30 μl.

[0109] Deglycosylation: Carbohydrate modification on the Fc domain of an antibody The rebuffered antibody was transferred to a 1.5 ml reaction tube and 4 μl EndoS enzyme and 4 μl 10xGlycobuffer (New England BioLabs, P0741L) were added to the antibody. RNAse-free ultrapure water was added up to 44 μl. The reaction was mixed by pipetting up and down. The antibody was incubated for 1 hour at 37° C. Afterwards, the deglycosylated antibody was rebuffered in 1xTBS (20 mM Tris-HCL; 150 mM NaCl; pH 7.6). For this, the deglycosylated antibody is applied to a 100 kD ultrafiltration column. To remove the deglycosylation buffer from the antibody solution, a rebuffer step was performed twice by adding a volume of 450 μl 1xTBS, the column was placed in a 2 ml collection tube and centrifuged at 14,000 g for 3 minutes at 4° C., and these steps were repeated once more. The flow-through was discarded. The column was inverted into a new collection tube and the antibody was collected by a brief spin (1,000 g, 20 s). The flow-through volume was approximately 20-30 μl.

[0110] MST binding assay: Glycosylated and non-deglycosylated trastuzumab antibodies are used, with or without blocking of lysine primary amine residues. The effect of blocking primary lysine residues was investigated. The experiment examines whether non-covalent binding occurs between antibodies and DNA oligonucleotides based on charge-related interactions between positively charged lysine residues of the antibody and negatively charged ssDNA oligonucleotides. The Monolith Protein Labeling Kit RED-NHS 2nd Generation kit was used according to the manufacturer's protocol including labeling and dye removal. The dye carries a reactive NHS-ester group that reacts with primary amines (lysine residues) to form covalent bonds. Thus, lysine primary amine residues are blocked. The RED dye is suitable for Monolith and Monolith NT. Automated instruments with RED detectors (Nano and Pico) and Dianthus NT.23 series. Ligand oligonucleotides (name: LIGO 5'-TTTTTGGTGACGATCCCGCAAAATCCAATGATGAGCACTTTTTGCAAGCCTCAGCGACC-3' 59 bp) (SEQ ID NO: 1) was used as indicated in the assay setup. [Table 2]

[0111] The results are shown in Figure 4. [Table 3]

[0112] The results are shown in Figure 5. [Table 4]

[0113] The results are shown in Figure 6. [Table 5]

[0114] The results are shown in Figure 7.

[0115] result Microscale thermophoresis (MST) was used for biophysical analysis of interactions between biomolecules. MST was used for temperature-induced fluorescence changes of antibody targets as a function of the concentration of non-fluorescent oligonucleotide ligands. MST measurements were performed to identify the binding ability between the ssDNA oligonucleotides used for labeling the antibodies and the antibodies themselves. Under autofluorescence (based on tryptophan fluorescence) conditions for the antibody targets, oligonucleotide concentrations higher than 0.1 mM showed characteristic binding curves, which were detected for both glycosylated and non-glycosylated trastuzumab antibodies (Figures 4 and 5). On the other hand, under conditions blocking the antibody lysine residues, no such binding curves were detected (Figures 6 and 7). The experimental results confirm that the non-covalent binding between the antibody and DNA oligonucleotides is based on charged interactions between the antibody (assuming positively charged lysine) and the negatively charged ssDNA oligonucleotides.

[0116] Example 3 - Alternative Highly Efficient Protocol for Antibody Labeling Rebuffering 100μg Trastuzumab antibody Briefly, a 100 kD ultrafiltration column (Sigma, UFC510096) was used to purify the antibody, adding a volume of 450 μl of UPW, ultrapure water (UPW) (Fisher Scientific, 2436574), centrifuging at 14,000 g for 3 min at 4 °C, and discarding the flow-through. This process was repeated once more. The antibody was collected by inverting the column into a new collection tube and briefly spinning (1,000 g, 20 s). The volume of the flow-through is approximately 20-30 μl. A deglycosylation step was performed by adding 3 μl of EndoS (New England BioLabs, P0741L), 3 μl of 10xGlyco buffer (New England BioLabs, P0741L), and UPW to a total volume of 30 μl to 20 μl of rebuffered antibody. The mixture was incubated at 37 °C for 1 h covered with parafilm. For UDP-GalNAz conjugation, 250 μl of UPW was added to one vial of 2.5 mg UDP-GalNAz and reconstituted for 20 min. To the deglysolated antibody reaction, 0.5 μl of buffer additive (Actome), 3 μl of reconstituted GalNAz and UPW were added to a total volume of 43.5 μl and mixed. After mixing, 1.3 μl of GalT (Actome) was added, mixed, and incubated overnight at 30° C., covered with parafilm and protected from light.

[0117] UDP-GalNAz was removed using a 100 kD ultrafiltration column (Sigma, UFC510096). A volume of 400 μl of 1xTBS, 20 mM Tris-HCL; 150 mM NaCl; pH 7.6) was added, centrifuged at 14,000 g for 10 min at 4°C, and the flow-through was discarded. This process was repeated once more. The column was inverted into a new collection tube and the antibody was collected by a short spin (1,000 g, 20 s). The volume of the flow-through was approximately 20-30 μl.

[0118] Click chemistry was performed by adding 2 μl of 1 mM 5'-DBCO-PEG4-oligonucleotide to the antibody preparation, mixing on a vortex mixer, then spinning briefly, covered with parafilm, and incubating overnight at 4°C. 4 μl of the labeled antibody solution was analyzed using a Bioanalyzer 2100 (Agilent) Protein 230 kit according to the manufacturer's instructions. The labeling efficiency was calculated:

number

[0119] 9 shows that the method produces oligonucleotide-labeled trastuzumab with a labeling efficiency of 99.2%. The 26 kD peak represents the light chain, the 52.1 kD peak represents the unlabeled heavy chain of the antibody, and the labeled heavy chain of the antibody is 74 kD.

[0120] Using the same protocol for antibody labeling, efficiency was determined using different concentrations of 5'-DBCO-PEG4 oligonucleotide instead of 2 μl of 1 mM 5'-DBCO-PEG4 oligonucleotide; experiments were performed using 3 μl (0.15 mM), the default 2 μl (0.1 mM) (as seen in the protocol), 1.5 μl (0.07 mM) and 0.3 μl (0.015 mM) to demonstrate the concentration dependence of labeling efficiency.

[0121] result Using 3 μl (0.15 mM), the default 2 μl (0.1 mM) (see above), 1.5 μl (0.07 mM) and 0.3 μl (0.015 mM) of 1 mM 5′-DBCO-PEG4 oligonucleotide, a concentration dependence of labeling efficiency was demonstrated, confirming the measured MST affinity between the antibody and the nucleic acid as shown in Figure 9. This demonstrates that high oligonucleotide concentrations are necessary for high labeling efficiency resulting in virtually 100% labeling efficiency.

Claims

1. A process for labeling an antibody with an oligonucleotide, comprising: (a) reacting the antibody with an oligonucleotide conjugated to a reactive group to form a covalent bond between the oligonucleotide and the antibody; the concentration of said oligonucleotide conjugate is at least 1 μM; process.

2. (a) deglycosylating conserved N-glycosylated amino acids in the CH2 domain of the antibody heavy chain to form an deglycosylated antibody; (b) reacting the deglycosylated antibody with an oligonucleotide conjugated to a reactive group to form a covalent bond between the oligonucleotide and the deglycosylated antibody; Including; 2. The process of claim 1, wherein the concentration of the oligonucleotide conjugate is at least 1 μM.

3. 3. The process according to claim 1 or 2, wherein the reactive group is capable of reacting with a primary amine or a sulfhydryl group to form a covalent bond.

4. 4. The process of claim 3, wherein the reactive group capable of reacting with a primary amine is selected from isothiocyanates, isocyanates, acyl azides, NHS esters, sulfonyl chlorides, aldehydes, glyoxals, epoxides, oxiranes, carbonates, aryl halides, imidoesters, carbodiimides, anhydrides, and fluorophenyl esters.

5. 4. The process of claim 3, wherein the reactive group capable of reacting with a sulfhydryl group is selected from haloacetyl, maleimide, aziridine, acrylic alloy, arylating agent, vinyl sulfone, pyridyl disulfide, TNB thiol, and disulfide reducing agent.

6. A process for labeling an antibody with an oligonucleotide (a) deglycosylating conserved N-glycosylated amino acids in the CH2 domain of the antibody heavy chain; (b) attaching a functional group to the deglycosylated antibody to form a modified antibody; (c) reacting the modified antibody with an oligonucleotide conjugated to a reactive group to form a covalent bond between the oligonucleotide and the modified antibody. Including; the reactive group reacts with the functional group to form a covalent bond; the concentration of said oligonucleotide conjugate is at least 1 μM; process.

7. 7. The process of claim 6, wherein the functional and reactive groups are selected from: azide group and a cycloalkynyl or alkynyl group; thiol group and an N-maleimide group, an iodoacetamide, a chloroacteamide or a disulfide group; a ketone or an aldehyde group and a hydrazine, an acylhydrazine, an aniline or an alkoxyamine.

8. The process of claim 6 , wherein the cycloalkynyl group is a cyclooctyne group.

9. The process according to any one of claims 6 to 8, wherein a modified GlcNAc moiety is formed by attaching a sugar moiety that comprises said functional group.

10. 10. The process of claim 9, wherein the sugar moiety is a galactosamine moiety that is enzymatically attached using a β-1,4-galactosyltransferase.

11. The process according to any one of claims 1 to 10, wherein the antibody is an IgG antibody.

12. 12. The process of claim 11, wherein the N-glycosylated amino acid is asparagine 297.

13. The process according to any of claims 1 to 12, wherein the oligonucleotide contains from 30 to 150 nucleotides.

14. The process according to any one of claims 2 to 13, wherein the deglycosylation is carried out using an Fc-specific endoglycosidase.

15. An antibody labelled with an oligonucleotide by the process according to any one of claims 1 to 14.

16. (i) an oligonucleotide conjugated to a reactive group; and optionally (ii) a compound that contains a functional group capable of forming a modified GlcNAc moiety; and / or (iii) an Fc-specific endoglycosidase; and / or (iv) β-1,4-galactosyltransferase A kit for use in the process according to any one of claims 1 to 14 for labelling an antibody with an oligonucleotide comprising: